In addition to its role in vascular remodelling, Pyk2 has been identified as a pro-metastatic and pro-angiogenic molecule in several cancer models including small cell lung cancer [79,80], prostate cancer [81-83] and glioblastoma [41,58-60]. Here, PTK2B is linked to prostate carcinoma.